NP591835.RAuao76-8sfPhL-uNWjj GYkStPbTNuZjXfNajcMqcXww
has assertion: NP591835.RAuao76-8sfPhL-uNWjj GYkStPbTNuZjXfNajcMqcXww130 assertion
has provenance: NP591835.RAuao76-8sfPhL-uNWjj GYkStPbTNuZjXfNajcMqcXww130 provenance
has publication info: NP591835.RAuao76-8sfPhL-uNWjj GYkStPbTNuZjXfNajcMqcXww130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:46:14+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP591835.RAuao76-8sfPhL-uNWjj GYkStPbTNuZjXfNajcMqcXww130 assertion
type: Assertion
description: [These data indicate that activated Ras could substitute most of the upstream EGFR signal, and are consistent with the hypothesis that mutational activation of targets immediately downstream from the EGFR could induce the secondary resistance to gefitinib in patients with lung cancer carrying EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/17270025
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0